BioCatalyst

TVTX — Travere Therapeutics, Inc. catalysts

2 verified catalyst event(s) for Travere Therapeutics, Inc. (ticker TVTX). Each is linked to its official source. Verified as of 2026-11-02.

Next verified catalyst

2027-03-01 — Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomeruloscle · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glo
Phase 4 · Proteinuria, Immunoglobulin A (IgA) Nephropathy
 TVTX Travere Therapeutics, Inc. Sparsentan ClinicalTrials.gov ↗
✓ Source-checked 2026-11-02
Sponsor-projected date — can change
2027-03-12
in 4mo
ESTIMATED
 READOUT
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2 · Focal Segmental Glomerulosclerosis, Minimal Change Disease
 TVTX Travere Therapeutics, Inc. Sparsentan, Sparsentan, Sparsentan ClinicalTrials.gov ↗
✓ Source-checked 2026-11-02
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.